Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Assessing Availability of New Drugs in Europe, Japan, and the U.S.
An analysis of drug approval and reimbursement trends and timelines
Dec 11, 2024
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

The life sciences R&D ecosystem has brought more than 500 novel active substances (NASs) across a variety of therapeutic areas through regulatory approval in the United States, the European Union, and Japan from 2014-2022; however, patient access to these innovative treatments varies substantially across these regions, due to both regulatory approval processes and subsequent availability challenges. Understanding these dynamics is a crucial step in addressing these access disparities for public health policymakers, improving patient health outcomes, and fostering a more robust and competitive R&D environment worldwide.

This report aims to understand the current landscape of NAS approvals and availability across these regions and to identify areas where policy reforms can enhance patient access. The proportion of total NASs approved by each region and how quickly each region approved NASs is evaluated. Subsequently, the rate at which NASs achieve availability after approval and how long it takes to become available by country is assessed. By shedding light on the hurdles faced by drug developers and the impact of these challenges on patient outcomes, the findings intend to guide stakeholders in making informed decisions to bridge gaps in patient access and ensure that innovative treatments are available to those who need them most.

Key Findings:

  • A total of 545 NASs were approved by the U.S., EU, and/or Japan from 2014-2022, with nearly half (260) approved by all three regulatory bodies.
  • The U.S. approved the most NASs, approves NASs earlier on average than the EU and Japan, and has continued to increase its margin of exclusive approvals.
  • U.S. only NASs are concentrated in the oncology and neurology therapeutic areas, are most often developed by emerging biopharma (EBP) companies, and nearly half are first-in-class products.
  • Though Japan falls behind both the U.S. and EU in terms of total approved NASs (potentially due to drug developers not submitting their products), once approved they are almost always become available within a few months.
  • The EU countries vary in their rate of availability and time to availability, and the majority of the EU fall behind the U.S. in both metrics, highlighting potential unmet patient need in this region.

Other Findings:

  • Of the 545 NASs selected, 48% (260) have been approved by all three regulatory bodies (US, EU, and Japan).
  • Another 22% (121) have been approved by the U.S. and EU only (i.e., not approved in Japan), 6% (34) are approved by the U.S. and Japan only, and 1% (6) are approved by the EU and Japan only.
  • Of products only approved by one of the three regulatory bodies, 13% (69) have only been approved in the U.S., 2% (12) have only been approved in the EU, and 8% (43) have only been approved in Japan.
  • Between the U.S. and EU, a total of 502 NASs were approved by one or both regulatory bodies, and 85% (427) of these were approved by at least one of these two regions from 2014-2022.
  • Of the 329 NASs approved by both the FDA/EMA from 2014-2022, 79% (260) were approved in the U.S. first.
  • Across the 329 shared NASs, the mean and median time to approval is 0.4 years faster and 0.5 years faster in the U.S., respectively.
  • Between the U.S. and Japan, a total of 533 NASs were approved by one or both regulatory bodies, and 97% (519) of these were approved by at least one of these two regions from 2014-2022.
  • 53% (285) of NASs were approved in both the U.S. and Japan, while 35% (185) are U.S.-only and 9% (49) are Japan-only.
  • Across the 285 shared NASs, the mean and median time to approval is 2.8 years faster and 1.3 years faster in the U.S., respectively.
  • The U.S. has the highest absolute rate of availability, with its 318 available NASs constituting 58% of the full 545 NAS list.
  • Japan closely follows the U.S. in terms of available NASs at 55% (299); however, another 37% (202) out of all 545 NASs have never been approved in Japan.
  • When all 27 EU countries are considered, the proportion of NASs approved by EMA from 2014-2022 that achieved availability ranges from 52% down to only 2%.
  • Time to availability, which is the length of time from a NASs’ central approval date to the date which it achieves payer coverage within a given country, can vary by product, country, and (in the U.S.), by benefit type and payer channel.
  • 25 of the 27 EU countries have longer median delays to availability than the U.S., and 22 of the 27 EU countries have a median time to availability from approval of one year or longer for novel treatments.
  • The process of adding drugs to each country’s reimbursement list can be burdened by drawn out negotiations, budget limitations, and limited resources; for drug developers, this process can also prove challenging after receiving approval by the EMA due to the decentralized requirements and rules of each of the 27 EU countries.

Related solutions

Pricing and Market Access

Understand how payers, providers, and patients define value, and accelerate market access for new and innovative products.

Contact Us